Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A sitewide notice about NIH website changes and terminology during an AI-related transition was removed from the page.
    Difference
    1%
    Check dated 2026-11-09T12:34:38.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-02T12:01:32.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    An NIH announcement banner says websites are transitioning and notes that some content may use “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T11:23:46.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T12:15:04.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-12T14:43:51.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The clinical trial record and its study details are no longer displayed; the page shows a 403 Forbidden error instead.
    Difference
    22%
    Check dated 2026-10-05T14:59:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.